Defence Therapeutics Inc. fell 16.7% on Wednesday, October 28, 2026, on 4,500 shares. No headline about DTC came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
Defence Therapeutics Inc. (DTC:CSE) closed at $0.315 on November 2, 2026, down 10.00% on the day. The stock trades 66.1% below its 52-week high of $0.930 and 1.6% above its 52-week low of $0.310. Over the past year, it lost 54.5%. Defence Therapeutics Inc. is part of the Life Sciences sector.
In 252 trading sessions since October 30, 2025, DTC closed higher on 96 days (38%). Its best day was August 14, 2026 (+16.05%) and its worst was October 28, 2026 (-16.67%). The stock moved 10% or more in a single session 17 times. It opened at least 5% above the previous day's high 10 times.
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases.
Find more stocks like DTC with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.